

hVIVO plc
("hVIVO", the "Company" or the "Group")

Capital Markets Event and Trading Update on 17 July

hVIVO plc (AIM & Euronext: HVQ) a fast growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will be holding a Capital Markets Event at the Company's new state-of-the-art facility in Canary Wharf for analysts, institutional investors, and media on Wednesday 17 July 2024 at 10.00 am - 12.30 pm (BST). The Company also expects to announce a trading update for the six months ended 30 June 2024 on the same day.

The event will focus on the capabilities of the world's largest human challenge trial unit and how it will enhance and broaden hVIVO's services as well as covering the Group's trading update. CEO Yamin 'Mo' Khan will chair the event that will include speakers from across the Group, as well as a fireside chat with a number of external speakers discussing the utility of human challenge trials. There will also be an opportunity for attendees to take part in Q&A sessions with the speakers and to tour the laboratory and challenge trial unit.

Analysts, institutional investors and media are welcome to attend the in-person event. Due to restrictions on numbers, it will not be possible for all interested parties to attend in-person, however, a live webcast will be available on the Company's website for retail investors and others to view the presentations [here](#).

To register your interest for the event or webcast, please contact Walbrook PR on +44 20 7933 8780 or email hvivo@walbrookpr.com. A recording of the presentation will be made available on the Company's website after the event.

For further information please contact:

hVIVO plc Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer	+44 (0) 20 7756 1300
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward	+44 (0) 20 7220 0500
Peel Hunt LLP (Joint Broker) James Steel, Dr Christopher Golden	+44 (0) 20 7418 8900
Davy (Euronext Growth Adviser and Joint Broker) Anthony Farrell, Niall Gilchrist	+353 (0) 1 679 6363
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson	+44 (0) 20 7933 8780 or hvivo@walbrookpr.com +44 (0) 7796 794 663 / +44 (0) 7867 984 082 / +44 (0) 7747 515 393

Notes to Editors

About hVIVO

[hVIVO plc](#) (ticker: HVO) (formerly Open Orphan plc) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and

molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its [FluCamp](#) volunteer screening facilities in London and Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TSTQFLFBZDLLBBL